Nefopam Analgesic Efficacy for Cancer Pain: A 40-Patient Randomized Controlled Study

A randomized controlled study of 40 patients with moderate to severe cancer pain evaluated the analgesic efficacy of nefopam. The study, authored by Koravee Pasutharnchat, compared a nefopam group receiving three 20 mg doses every 8 hours against a placebo group receiving normal saline over 48 hours. Primary and secondary outcomes included significant pain reduction, morphine consumption, and incidence of side effects.

Use Cases

• Compare pain reduction outcomes between treatment and placebo groups based on the described primary outcome.
• Analyze morphine consumption patterns over 48 hours based on the described secondary outcome.
• Model the incidence of side effects associated with nefopam treatment based on the described secondary outcome.
• Benchmark analgesic efficacy for non-opioid cancer pain treatments based on the described study design.

Strengths

• Data originates from a randomized controlled study, a gold-standard design for clinical evidence.
• Study includes 40 patients, providing a specific sample size for analysis.
• Clear primary and secondary outcomes are defined, including pain reduction, morphine consumption, and side effects.

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• Last update date is unknown; freshness unverified.
• The sample size of 40 patients may limit the statistical power for some analyses.

Provenance

Source

Koravee Pasutharnchat, associated article published on F1000Research.

Collection Method

Data likely collected from a clinical trial as described in the randomized controlled study.